Archive 2017

2017

- 01 Dec 2017 – China Medical System Holdings Limited invests £3.0 million in Destiny Pharma
- 01 Dec 2017 – Regional development and commercialisation agreement finalised with China Medical System Holdings Limited
- 30 Oct 2017 – MRSA superbug spreading from hospitals across UK
- 09 Oct 2017 – United Nations group to meet in Berlin in October 2017 to discuss global issue of Anti-Microbial Resistance
- 27 Sep 2017 – Destiny Pharma to push ahead with next-generation antibiotic after £15 million IPO
- 27 Sep 2017 – Destiny Pharma announce interim results 27th September 2017
- 19 Sep 2017 – More support announced for new antibiotics
- 04 Sep 2017 – Framework Agreement with China Medical Systems
- 04 Sep 2017 – Admission and First Day of Dealings on AIM
- 01 Sep 2017 – Destiny Pharma plc publishes Supplementary AIM Admission Document
- 29 Aug 2017 – Destiny Pharma plc publishes AIM Admission Document
- 18 Aug 2017 – Notification of Intention to Admit Shares to Trading on the Alternative Investment Market of the London Stock Exchange
- 13 Jul 2017 – G20 Declaration on Combatting Antimicrobial Resistance (AMR) 7-8th July 2017
- 07 Jul 2017 – To the G20: Incentivise Antibacterial Drug R&D
- 07 Jul 2017 – Destiny’s Brainchild (South East Business Magazine)
- 14 Jun 2017 – Regulators from EU, U.S. and Japan join forces on antimicrobial trials
- Destiny Pharma in attendance at the 18th Bio€quity Europe Meeting, Paris, France
- 09 May 2017 – Destiny Board Member Elected to the Academy of Medical Sciences
- 13 Apr 2017 – Destiny Pharma announces appointment of new CEO
- Destiny Pharma to attend the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria
- Destiny Pharma to attend Bio-Europe Meeting, Barcelona, Spain
- Destiny Pharma to present at the 18th BioEquity Europe Meeting, Paris, France